Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of “Moderate Buy” from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $8.6667.

GANX has been the subject of several analyst reports. Roth Mkm reaffirmed a “buy” rating and set a $10.00 target price on shares of Gain Therapeutics in a report on Friday, December 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday, December 29th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a report on Friday, December 19th.

Gain Therapeutics Price Performance

Shares of NASDAQ:GANX opened at $1.94 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.52 and a current ratio of 2.52. The company has a market capitalization of $74.61 million, a PE ratio of -3.18 and a beta of 0.05. The stock has a fifty day moving average of $2.36 and a 200-day moving average of $2.25. Gain Therapeutics has a one year low of $1.41 and a one year high of $4.34.

Institutional Trading of Gain Therapeutics

A number of hedge funds have recently modified their holdings of GANX. Sprott Inc. bought a new position in shares of Gain Therapeutics during the 4th quarter valued at $39,000. Commonwealth Equity Services LLC bought a new stake in Gain Therapeutics in the fourth quarter worth $41,000. Millennium Management LLC acquired a new position in Gain Therapeutics during the fourth quarter worth $45,000. Engineers Gate Manager LP bought a new position in Gain Therapeutics during the fourth quarter valued at about $47,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Gain Therapeutics in the third quarter worth about $28,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.